Brodalumab, an anti-interleukin-17 receptor A monoclonal antibody, in axial spondyloarthritis: 68-week results from a phase 3 study. (2022)
https://pubmed.ncbi.nlm.nih.gov/36130275/

The Risk of Major Adverse Cardiovascular Events in Ankylosing Spondylitis Patients With a History of Acute Anterior Uveitis: A Nationwide, Population Based Cohort Study (2022)
https://pubmed.ncbi.nlm.nih.gov/35872802/

Risk of Ankylosing Spondylitis in Patients With Endometriosis: A Population-Based Retrospective Cohort Study (2022)
https://pubmed.ncbi.nlm.nih.gov/35784295/

Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial (2021)
https://pubmed.ncbi.nlm.nih.gov/33827787/

Increased Risk of Inflammatory Bowel Disease Among Patients With Ankylosing Spondylitis: A 13-Year Population-Based Cohort Study (2020)
https://pubmed.ncbi.nlm.nih.gov/33123163/

Risk of ankylosing spondylitis following human papillomavirus infection: A nationwide, population-based, cohort study (2020)
https://pubmed.ncbi.nlm.nih.gov/32417193/

Taiwan Rheumatology Association consensus recommendations for the management of axial spondyloarthritis (2020)
https://pubmed.ncbi.nlm.nih.gov/31777200/